The S1900A substudy of the LUNG-MAP trial evaluated the role of the PARP inhibitor rucaparib in advanced NSCLC with BRCA1/2 mutations or genomic loss of heterozygosity (LOH) as a phenotypic marker for homologous recombination deficiency (HRD). Here, PARP1 is linked to non-small cell lung carcinoma.